Splicing control by PHF5A is crucial for melanoma cell survival

Abstract

Abnormalities in alternative splicing are a hallmark of cancer formation. In this study, we investigated the role of the splicing factor PHD finger protein 5A (PHF5A) in melanoma. Malignant melanoma is the deadliest form of skin cancer, and patients with a high PHF5A expression show poor overall survival. Our data revealed that an siRNA-mediated downregulation of PHF5A in different melanoma cell lines leads to massive splicing defects of different tumour-relevant genes. The loss of PHF5A results in an increased rate of apoptosis by triggering Fas- and unfolded protein response (UPR)-mediated apoptosis pathways in melanoma cells. These findings are tumour-specific because we did not observe this regulation in fibroblasts. Our study identifies a crucial role of PHF5A as driver for melanoma malignancy and the described underlying splicing network provides an interesting basis for the development of new therapeutic targets for this aggressive form of skin cancer.

References

[1] SchadendorfD, van Akkooi ACJ, BerkingC, et al. Melanoma. Lancet. 2018;392:971-984.

[2] GreeneMH, ElderDE, GuerryD, Epstein MN, GreeneMH, Van HornM. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984;15:1147-1165.

[3] WagleN, EmeryC, BergerMF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29:3085-3096.

[4] AsciertoPA, Kirkwood JM, GrobJJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.

[5] PoulikakosPI, Persaud Y, JanakiramanM, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387-390.

[6] InoueD, ChewGL, LiuB, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574:432-436.

[7] LeclairNK, Brugiolo M, UrbanskiL, et al. Poison exon splicing regulates a coordinated network of SR protein expression during differentiation and tumorigenesis. Mol Cell. 2020;80:648-665.e9.

[8] WanL, LinKT, RahmanMA, et al. Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer. Cancer Discov. 2023;13:1678-1695.

[9] KahlesA, Van Lehmann K, ToussaintNC, et al. Comprehensive analysis of alternative splicing across tumors from 8, 705 patients. Cancer Cell. 2018;34:211-224.e6. doi:10.1016/J.CCELL.2018.07.001

[10] OlteanS, BatesDO. Hallmarks of alternative splicing in cancer. Oncogene. 2014;33:5311-5318.

[11] WangZ, WangS, QinJ, et al. Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12. Nat Commun. 2022;13:6246.

[12] WillCL, Lührmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol. 2011;3:1-2. doi:10.1101/CSHPERSPECT.A003707

[13] TengT, TsaiJH, PuyangX, et al. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex. Nat Commun. 2017;8:15522.

[14] TrappeR, AhmedM, GläserB, et al. Identification and characterization of a novel murine multigene family containing a PHD-finger-like motif. Biochem Biophys Res Commun. 2002;293:816-826.

[15] BegumNA, HaqueF, StanlieA, et al. Phf5a regulates DNA repair in class switch recombination via p400 and histone H2A variant deposition. EMBO J. 2021;40:e106393.

[16] OltraE, VerdeF, WernerR, D’Urso G. A novel RING-finger-like protein Ini1 is essential for cell cycle progression in fission yeast. J Cell Sci. 2004;117:967-974.

[17] StrikoudisA, Lazaris C, TrimarchiT, et al. Regulation of transcriptional elongation in pluripotency and cell differentiation by the PHD-finger protein Phf5a HHS public access author manuscript. Nat Cell Biol. 2016;18:1127-1138.

[18] YangY, ZhuJ, ZhangT, et al. PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma. J Exp Clin Cancer Res. 2018;37:1-14.

[19] ZhengYZ, XueMZ, ShenHJ, et al. PHF5A epigenetically inhibits apoptosis to promote breast cancer progression. Cancer Res. 2018;78:3190-3206.

[20] HubertCG, Bradley RK, DingY, et al. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev. 2013;27:1032-1045.

[21] LämmerhirtL, Kappelmann-fenzl M, FischerS, et al. Knockdown of Lamin B1 and the corresponding Lamin B receptor leads to changes in heterochromatin state and senescence induction in malignant melanoma. Cells. 2022;11:2154.

[22] NortonSS, Vaquero-Garcia J, LahensNF, GrantGR, BarashY. Outlier detection for improved differential splicing quantification from RNA-seq experiments with replicates. Bioinformatics. 2018;34:1488-1497.

[23] FrankishA, Diekhans M, JungreisI, et al. GENCODE 2021. Nucleic Acids Res. 2021;49:D916-D923.

[24] BaileyTL. STREME: accurate and versatile sequence motif discovery. Bioinformatics. 2021;37:2834-2840.

[25] SeefriedF, HallerL, FukudaS, et al. Nuclear AREG affects a low-proliferative phenotype and contributes to drug resistance of melanoma. Int J Cancer. 2022;151:2244-2264.

[26] Kappelmann-FenzlM, Gebhard C, MatthiesAO, KuphalS, RehliM, BosserhoffAK. C-Jun drives melanoma progression in PTEN wild type melanoma cells. Cell Death Dis. 2019;10:584.

[27] ParmenterTJ, Kleinschmidt M, KinrossKM, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423-433.

[28] CretuC, Schmitzová J, Ponce-SalvatierraA, et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol Cell. 2016;64:307-319.

[29] WillCL, UrlaubH, AchselT, Gentzel M, WilmM, LührmannR. Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J. 2002;21:4978-4988.

[30] YangSY, XieYF, ZhangTM, et al. Inositol monophosphatase 1 (IMPA1) promotes triple-negative breast cancer progression through regulating mTOR pathway and EMT process. Cancer Med. 2023;12:1602-1615.

[31] WilmsC, Kroeger CM, HainzlAV, et al. MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth. Oncotarget. 2017;8:67287-67299.

[32] HuY-H, ZhangY, JiangL-Q. et al. WDFY1 mediates TLR3/4 signaling by recruiting TRIF. EMBO Rep. 2015;16:447-455.

[33] HuangS, DeGuzman A, BucanaCD, FidlerIJ. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell Mol Ther. 2000;6:9-17.

[34] RichmondA. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002;2:664-674.

[35] DuttaS, RoyS, PolavaramNS, et al. NRP2 transcriptionally regulates its downstream effector WDFY1. Sci Rep. 2016;6:23588.

[36] KimY, OsbornDP, LeeJ, et al. WDR11-mediated hedgehog signalling defects underlie a new ciliopathy related to Kallmann syndrome. EMBO Rep. 2018;19:269-289.

[37] PengZP, HuangSF, LiJJ, TangXK, WangXY, Li HM. The effects of hedgehog signaling pathway on the proliferation and apoptosis of melanoma cells. J Oncol. 2022;2022:1-9.

[38] AleksanderSA, Balhoff J, CarbonS, et al. The gene ontology knowledgebase in 2023. Genetics. 2023;224:iyad031. doi:10.1093/genetics/iyad031

[39] SzklarczykD, GableAL, NastouKC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49:10800.

[40] MarciniakSJ, YunCY, OyadomariS, et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004;18:3066-3077.

[41] Van GalenP, KresoA, MbongN, et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature. 2014;510:268-272.

[42] HazeK, Yoshida H, YanagiH, YuraT, MoriK. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell. 1999;10:3787-3799.

[43] YeJ, RawsonRB, KomuroR, et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell. 2000;6:1355-1364.

[44] YangX, Coulombe-Huntington J, KangS, IakouchevaLM, XiaY, VidalM. Widespread expansion of protein interaction capabilities by alternative splicing. Cell. 2016;164:805-817.

[45] WangJ, ZhangJ, LiK, ZhaoW, CuiQ. SpliceDisease database: linking RNA splicing and disease. Nucleic Acids Res. 2012;40:D1055-D1059.

[46] HeRQ, ZhouXG, YiQY, et al. Prognostic signature of alternative splicing events in bladder urothelial carcinoma based on Spliceseq data from 317 cases. Cell Physiol Biochem. 2018;48:1355-1368.

[47] YangX, HuangWT, HeRQ, et al. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from the cancer genome atlas. J Transl Med. 2019;17:1-21.

[48] LiuC, LiG, ZhengS, et al. PHF5A regulates the expression of the DOCK5 variant to promote HNSCC progression through p38 MAPK activation. Biol Direct. 2023;18:39.

[49] YangQ, ZhangJ, XuS, et al. Knockdown of PHF5A inhibits migration and invasion of HCC cells via downregulating NF-κB signaling. Biomed Res Int. 2019;2019:1-9.

[50] ChangY, ZhaoY, WangL, et al. PHF5A promotes colorectal cancerprogression by alternative splicing of TEAD2. Mol Ther Nucleic Acids. 2021;26:1215-1227.

[51] GoutS, Brambilla E, BoudriaA, et al. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS One. 2012;7:e46539.

[52] DuJX, LuoYH, ZhangSJ, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Exp Clin Cancer Res. 2021;40:171.

[53] WangH, ZhouM, ShiB, et al. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia. 2011;13:461.

[54] KatohM, KatohM. FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Int J Oncol. 2003;22:1155-1159. doi:10.3892/IJO.22.5.1155/HTML

[55] GohelMS, TaylorM, EarnshawJJ, Heather BP, PoskittKR, WhymanMR. Risk factors for delayed healing and recurrence of chronic venous leg ulcers—an analysis of 1324 legs. Eur J Vasc Endovasc Surg. 2005;29:74-77.

[56] StanleyA, OslerT. Senescence and the healing rates of venous ulcers. J Vasc Surg. 2001;33:1206-1211.

[57] LiW, Simarro M, KedershaN, AndersonP. FAST is a survival protein that senses mitochondrial stress and modulates TIA-1-regulated changes in protein expression. Mol Cell Biol. 2004;24:10718-10732.

[58] ReadA, Schröder M. The unfolded protein response: an overview. Biology (Basel). 2021;10:384.

[59] MaddenE, LogueSE, HealySJ, Manie S, SamaliA. The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance. Biol Cell. 2019;111:1-17.

[60] ZimmermannT, Staebler S, TaudteRV, et al. Cold atmospheric plasma triggers apoptosis via the unfolded protein response in melanoma cells. Cancers (Basel). 2023;15:1064.

[61] FribleyA, ZhangK, KaufmanRJ. Regulation of apoptosis by the unfolded protein response. Methods Mol Biol. 2009;559:191.

[62] FawcettTW, Martindale JL, GuytonKZ, HaiT, Holbrook NJ. Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. Biochem J. 1999;339:135.

[63] MaY, BrewerJW, Alan DiehlJ, Hendershot LM. Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J Mol Biol. 2002;318:1351-1365.

[64] LeeA-H, Iwakoshi NN, GlimcherLH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol. 2003;23:7448-7459.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.